BOSTON SCIENTIFIC CORP

ISIN: US1011371077 WKN: 101137107 Asset Class: Stock

E-mail: -



Company Profile

Debt-equity ratio

01752-1234 Marlborough

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Financial figures, Fiscal year: from 01.01. to 31.12. 2023 Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity

- manorar rigaros	Additio	Liabilities and equity	Addeta	Liabilities and equity	Addeta	Liabilities and equity
Current assets	6,514,000,000		5,760,000,000		6,317,000,000	
Common stock capital		17,000,000		17,000,000		17,000,000
Fixed assets	28,622,000,000		26,709,000,000		25,912,000,000	
Equity capital of a company		19,530,000,000		17,573,000,000		16,622,000,000
Cash and cash equivalents	995,000,000		1,077,000,000		2,113,000,000	
Accrued liabilities		172,000,000		212,000,000		284,000,000
Other assets	-		-		-	
Current liabilities		4,933,000,000		3,803,000,000		4,274,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		10,673,000,000		11,093,000,000		11,333,000,000
Different income		-		-		-
Other liabilities		1,406,000,000		1,475,000,000		1,546,000,000
Total assets	35,136,000,000	35,136,000,000	32,469,000,000	32,469,000,000	32,229,000,000	32,229,000,000

Balance notes			
	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	48,000	45,000	41,000
Equity ratio	56.29%	54.12%	51.57%

77.65%

84.77%

Others			
	2023	2022	2021
Tax Expense Rate	19.80%	38.83%	3.35%

93.89%

BOSTON SCIENTIFIC CORP

ISIN: **US1011371077** WKN: **101137107** Asset Class: **Stock**

Income statement			
	2023	2022	2021
Turnover	14,240,000,000	12,682,000,000	11,888,000,000
Net income	1,593,000,000	698,000,000	1,040,000,000
EBIT	2,058,211,500	1,468,835,500	1,308,598,900
Operating income before taxes	1,985,000,000	1,141,000,000	1,076,000,000
Cash Flow	2,503,000,000	1,526,000,000	1,871,000,000
Net interest income	-250,000,000	-454,000,000	-345,000,000
Research and development expenses	1,414,000,000	1,323,000,000	1,204,000,000
Income taxes	393,000,000	443,000,000	36,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	273,200	259,530	267,016

Board of Directors

Members of Management Board		
Cheryl Pegus	Member of Board of Directors	
Ellen Zane	Member of Board of Directors	
Jessica Mega	Member of Board of Directors	
Charles Dockendorff	Member of Board of Directors	
David Habiger	Member of Board of Directors	
David Wichmann	Member of Board of Directors	
Edward Ludwig	Member of Board of Directors	
John Sununu	Member of Board of Directors	
Susan Morano	Member of Board of Directors	
Yoshiaki Fujimori	Member of Board of Directors	
Michael F. Mahoney	Chairman of Managing Board	
Arthur Butcher	Member of Executive Committee	
Daniel J. Brennan	Member of Executive Committee	
Eric Thépaut	Member of Executive Committee	
Jeff Mirviss	Member of Executive Committee	
Jodi Eddy	Member of Executive Committee	
Joseph M. Fritzgerald	Member of Executive Committee	
Kenneth Stein	Member of Executive Committee	
Mary Beth Moynihan	Member of Executive Committee	